Contact Force Guided Ablation Versus Conventional Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation
Launched by DEUTSCHES HERZZENTRUM MUENCHEN · Jun 27, 2016
Trial Information
Current as of May 13, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
Eligibility criteria
- Inclusion Criteria:
- • Patients (\>=18 und \< 80 years) with symptomatic paroxysmal AF
- • At least one unsuccessful attempt of antiarrhythmic drug (betablocker or class I oder III).
- • Oral anticoagulation with phenprocoumone, warfarine or DOAKs for at least 4 weeks prior to ablation with weekly documented INR \> 2..
- • Withdrawal of antiarrhythmic drugs at least 3 half times prior to ablation except amiodarone.
- Exclusion Criteria:
- • Left atrial thrombus
- • Contraindications for oral anticoagulation or adenosin
About Deutsches Herzzentrum Muenchen
Deutsches Herzzentrum München (German Heart Center Munich) is a leading institution in cardiovascular medicine, dedicated to advancing research, treatment, and education in heart health. Affiliated with the Technical University of Munich, the center specializes in innovative clinical trials aimed at improving diagnostic and therapeutic approaches for heart diseases. With a multidisciplinary team of experts, state-of-the-art facilities, and a commitment to patient-centered care, Deutsches Herzzentrum München is at the forefront of developing novel interventions and enhancing clinical outcomes in cardiovascular health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Munich, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials